Literature DB >> 28281191

Lumbar interbody fusion with utilization of recombinant human bone morphogenetic protein: a retrospective real-life study about 277 patients.

Stéphane Litrico1, Tristan Langlais2, Florent Pennes1, Antoine Gennari1, Philippe Paquis1.   

Abstract

The purpose of this study was to report an independent real-life experience about the use of recombinant human bone morphogenetic protein 2 in lumbar interbody fusion with a special focus on complications. This is a retrospective single-center cohort study between 2007 and 2013 including 277 patients treated for anterior or posterior lumbar fusion with recombinant human bone morphogenetic protein 2. We report the complications occurring during the 12 first postoperative months and analyze the fusion rate on X-rays. There are 58 cases (22.8%) of clinical complications. In 15 cases (5.9%), these complications were related to the use of recombinant human bone morphogenetic protein 2. Only one patient (0.4%) required a new intervention due to recombinant human bone morphogenetic protein 2. Fusion rate at 1 year was 98%. The low rate of specific complication suggests that recombinant human bone morphogenetic protein 2 can be safe and effective in anterior and posterior interbody fusion when used with simple precautions.

Entities:  

Keywords:  Complications; Heterotopic ossification; Lumbar interbody fusion; Radiculitis; Recombinant human bone morphogenetic protein; Retrospective cohort

Mesh：

Substances：

Year:  2017        PMID： 28281191     DOI： 10.1007/s10143-017-0834-z

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN： 0344-5607            Impact factor:   3.042


  47 in total

1.  Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion.

Authors:  Lisa B E Shields; George H Raque; Steven D Glassman; Mitchell Campbell; Todd Vitaz; John Harpring; Christopher B Shields
Journal:  Spine (Phila Pa 1976)       Date:  2006-03-01       Impact factor: 3.468

2.  Complications with recombinant human bone morphogenic protein-2 in posterolateral spine fusion: a consecutive series of 1037 cases.

Authors:  Steven D Glassman; Jennifer Howard; John Dimar; Alexander Sweet; Greg Wilson; Leah Carreon
Journal:  Spine (Phila Pa 1976)       Date:  2011-10-15       Impact factor: 3.468

3.  Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.

Authors:  Cameron Louis Adams; Kathryn Ogden; Iain Kilpatrick Robertson; Stephen Broadhurst; David Edis
Journal:  Spine (Phila Pa 1976)       Date:  2014-01-15       Impact factor: 3.468

4.  Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft.

Authors:  J Kenneth Burkus; Harvinder S Sandhu; Matthew F Gornet
Journal:  Spine (Phila Pa 1976)       Date:  2006-04-01       Impact factor: 3.468

5.  Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study.

Authors:  Garet C Comer; Micah W Smith; Eric L Hurwitz; Kyle A Mitsunaga; Robert Kessler; Eugene J Carragee
Journal:  Spine J       Date:  2012-10-22       Impact factor: 4.166

6.  A carbon fiber implant to aid interbody lumbar fusion. Two-year clinical results in the first 26 patients.

Authors:  J W Brantigan; A D Steffee
Journal:  Spine (Phila Pa 1976)       Date:  1993-10-15       Impact factor: 3.468

7.  Epidemiological trends in the utilization of bone morphogenetic protein in spinal fusions from 2002 to 2011.

Authors:  Kern Singh; Sreeharsha V Nandyala; Alejandro Marquez-Lara; Steven J Fineberg
Journal:  Spine (Phila Pa 1976)       Date:  2014-03-15       Impact factor: 3.468

8.  Complications associated with single-level transforaminal lumbar interbody fusion.

Authors:  Jeffrey A Rihn; Ravi Patel; Junaid Makda; Joseph Hong; David G Anderson; Alexander R Vaccaro; Alan S Hilibrand; Todd J Albert
Journal:  Spine J       Date:  2009-05-30       Impact factor: 4.166

9.  Six-year outcomes of anterior lumbar interbody arthrodesis with use of interbody fusion cages and recombinant human bone morphogenetic protein-2.

Authors:  J Kenneth Burkus; Matthew F Gornet; Thomas C Schuler; Thomas J Kleeman; Thomas A Zdeblick
Journal:  J Bone Joint Surg Am       Date:  2009-05       Impact factor: 5.284

10.  Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5 randomized controlled trials: clinical article.

Authors:  J Kenneth Burkus; Randall F Dryer; John H Peloza
Journal:  J Neurosurg Spine       Date:  2012-11-30
View more
  3 in total

1.  Evaluation of an increased strut porosity silicate-substituted calcium phosphate, SiCaP EP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open-label study.

Authors:  Ciaran Bolger; Drew Jones; Steven Czop
Journal:  Eur Spine J       Date:  2019-03-05       Impact factor: 3.134

Review 2.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

3.  Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial.

Authors:  Jun-Young Choi; Hyun-Jin Park; Sang-Min Park; Chang-Nam Kang; Kwang-Sup Song
Journal:  J Orthop Surg Res       Date:  2022-08-31       Impact factor: 2.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.